DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chang, Dong-Yeop | ko |
dc.contributor.author | Shin, Eui-Cheol | ko |
dc.date.accessioned | 2009-11-30T08:34:27Z | - |
dc.date.available | 2009-11-30T08:34:27Z | - |
dc.date.created | 2012-02-06 | - |
dc.date.created | 2012-02-06 | - |
dc.date.issued | 2009-07 | - |
dc.identifier.citation | JOURNAL OF LEUKOCYTE BIOLOGY, v.86, no.1, pp.33 - 39 | - |
dc.identifier.issn | 0741-5400 | - |
dc.identifier.uri | http://hdl.handle.net/10203/13708 | - |
dc.description.abstract | Chronic, persistent HCV infection is a public health issue. It often progresses to life-threatening complications, including liver cirrhosis and hepatocellular carcinoma. The current standard therapy is a combination of pegylated IFN-alpha and ribavirin. This therapy results in a sustained virologic response in only 50% of patients infected with HCV genotype 1 and is often accompanied with substantial side-effects. Therefore, it is imperative to develop novel therapies with higher efficacy and less substantial side-effects. Impaired immune responses to HCV are key features of chronic HCV infection; thus, intervention strategies typically involve boosting the immune responses against HCV. These immune-based therapies for chronic HCV infection include therapeutic vaccines, antagonists of T cell inhibitory factors, anti-HCV neutralizing antibodies, cytokines, and agonists for TLRs. Currently, various types of immune-based therapies are under development that might be used as a monotherapy or in combination with other antiviral drugs for the treatment of chronic HCV infection. J. Leukoc. Biol. 86: 33-39; 2009. | - |
dc.language | English | - |
dc.language.iso | en_US | en |
dc.publisher | FEDERATION AMER SOC EXP BIOL | - |
dc.subject | CHRONIC VIRAL-INFECTION | - |
dc.subject | T-CELL RESPONSES | - |
dc.subject | RECOMBINANT HUMAN INTERLEUKIN-12 | - |
dc.subject | NECROSIS-FACTOR-ALPHA | - |
dc.subject | VIRUS-INFECTION | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | GAMMA-INTERFERON | - |
dc.subject | PD-1 EXPRESSION | - |
dc.subject | MONOCLONAL-ANTIBODY | - |
dc.subject | CONTROLLED TRIAL | - |
dc.title | Immune-based therapy for chronic hepatitis C | - |
dc.type | Article | - |
dc.identifier.wosid | 000267488700006 | - |
dc.identifier.scopusid | 2-s2.0-68849127031 | - |
dc.type.rims | ART | - |
dc.citation.volume | 86 | - |
dc.citation.issue | 1 | - |
dc.citation.beginningpage | 33 | - |
dc.citation.endingpage | 39 | - |
dc.citation.publicationname | JOURNAL OF LEUKOCYTE BIOLOGY | - |
dc.identifier.doi | 10.1189/JLB.1208772 | - |
dc.embargo.liftdate | 9999-12-31 | - |
dc.embargo.terms | 9999-12-31 | - |
dc.contributor.localauthor | Shin, Eui-Cheol | - |
dc.type.journalArticle | Review | - |
dc.subject.keywordAuthor | HCV | - |
dc.subject.keywordAuthor | immunotherapy | - |
dc.subject.keywordAuthor | T cell | - |
dc.subject.keywordAuthor | cytokine | - |
dc.subject.keywordPlus | CHRONIC VIRAL-INFECTION | - |
dc.subject.keywordPlus | T-CELL RESPONSES | - |
dc.subject.keywordPlus | RECOMBINANT HUMAN INTERLEUKIN-12 | - |
dc.subject.keywordPlus | NECROSIS-FACTOR-ALPHA | - |
dc.subject.keywordPlus | VIRUS-INFECTION | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | GAMMA-INTERFERON | - |
dc.subject.keywordPlus | PD-1 EXPRESSION | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | CONTROLLED TRIAL | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.